Levetiracetam for the treatment of alcohol withdrawal syndrome: A multicenter, prospective, randomized, placebo-controlled trial

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 720-725

  Richter, Christoph ^a,b   Hinzpeter, Axel ^a   Schmidt, Folkhard ^c   Kienast, Thorsten ^a   Preuss, Ulrich W ^d   Plenge, Thomas ^e   Heinz, Andreas ^a   Schaefer, Martin ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Vivantes Wenckebach Klinikum   (Germany)

^c KLINIKEN ESSEN MITTE   (Germany)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^e Department of Psychiatry and Psychotherapy   (Germany)

Author keywords

alcohol withdrawal; antiepileptics; diazepam; levetiracetam; treatment

Indexed keywords

DIAZEPAM; ETIRACETAM; MELPERONE; PARACETAMOL; PLACEBO; THIAMINE;

ADULT; AGED; ALCOHOL WITHDRAWAL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SINGLE DRUG DOSE; SLEEP DISORDER; TACHYCARDIA;

ADULT; ALCOHOLISM; ANTICONVULSANTS; DIAZEPAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 78649361521     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181faf53e     Document Type: Article

References (61)

1. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278:144-151.
2. Saitz R, Friedman LS, Mayo-Smith MF. Alcohol withdrawal: a nationwide survey of inpatient treatment practices. J Gen Intern Med. 1995;10:479-487.
3. Tanaka E, Nakamura T, Honda K. Toxicological interactions between alcohol and benzodiazepines. Chudoku Kenkyu. 2004;17:313-319.
4. Guglielminotti J, Maury E, Alzieu M, et al. Prolonged sedation requiring mechanical ventilation and continuous flumazenil infusion after routine doses of clorazepam for alcohol withdrawal syndrome. Intensive Care Med. 1999;25:1435-1436.
5. Peppers M. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996;16:49-57.
6. Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction. 2004;99: 165-173.
7. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.
8. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. Anesthesiology. 1990;72:926-938.
9. Soyka M, Schmidt F, Schmidt P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry. 2006;39:30-34.
10. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002; 21:55-64.
11. Soyka M, Schmidt P, Franz M, et al. Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci. 2006;256:395-401.
12. Bonnet U, Schafer M, Richter C, et al. Anticonvulsants in the treatment of alcoholism. Fortschr Neurol Psychiatr. 2009;77: 192-202.
13. Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry. 1978;133:1-14.
14. De Witte P, Pinto E, Ansseau M, et al. Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev. 2003;27:189-197.
15. Otsuki K, Morimoto K, Sato K, et al. Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats. Epilepsy Res. 1998;31:101-112.
16. Morimoto K, Sato H, Sato K, et al. BW1003C87, phenytoin and carbamazepine elevate seizure threshold in the rat amygdala-kindling model of epilepsy. Eur J Pharmacol. 1997;339:11-15.
17. Klitgaard H, Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 2003;5(suppl 1):S9YS16.
18. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998;284: 474-479.
19. Stratton SC, Large CH, Cox B, et al. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res. 2003;53:95-106.
20. Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 1994;35:181-188.
21. Malcolm R, Myrick H, Brady KT, et al. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict. 2001;(10 Suppl):16-23.
22. Chapman SA, Wacksman GP, Patterson BD. Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy. 2001;21:1549-1560.
23. Davis LL, Ryan W, Adinoff B, et al. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol. 2000; 20:1SY17S.
24. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32:554-563.
25. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-408.
26. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001;47:77-90.
27. Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology. 2004;63: 568-570.
28. Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure. 2003;12:617-620.
29. Chabolla DR, Harnois DM, Meschia JF. Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc. 2003;35: 1480-1481.
30. Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report. Epilepsia. 2004;45:559-560.
31. Nicolas JM, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos. 1999;27:250-254.
32. Bennett BLY, Lamberty Y, Bizot JC, et al. Levetiracetam prevents signs of alcohol withdrawal in mice. New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association, San Francisco. 2003;Abstract NR689:258.
33. Krebs M, Leopold K, Richter C, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol. 2006;26:347-349.
34. Wetterling T, Kanitz RD, Besters B, et al. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol. 1997;32:753-760.
35. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment For Alcohol Scale (CIWA-Ar). Br J Addict. 1989;84: 1353-1357.
36. Guy W. Clinical Global Impressions [CGI]. Rockville, MD: National Institute of Mental Health; 1976.
37. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
38. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
39. Horn S, Warnberg, Foster & ADRF, Translation in to German
40. K. Ackermann, S., J.Gordon H. ADS, Vol. Version 1.0: Zentralinstitut für Seelische Gesundheit, 1984, 1999.
41. Hamilton M. HAMAVHamilton Anxiety Scale. In: Guy W, ed. ECDEU Assessment, Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976: 193-198.
42. Hamilton M. HAMDVHamilton Depression Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:193-198.
43. European-Medicines-Agency. ICH Topic E 6 (R1) Guideline for Good Clinical Practice. London, July 2002.
44. Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf. 2004;3:415-424.
45. Carreno M. Levetiracetam. Drugs Today (Barc). 2007;43:769-794.
46. Diaz RA, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist. 2008;14:S55YS65.
47. Myrick H, Taylor B, LaRowe S, et al. A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal. J Psychoactive Drugs. 2005;37:409-414.
48. Stuppaeck CH, Deisenhammer EA, Kurz M, et al. The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome. Alcohol Alcohol. 1996;31:109-111.
49. Schik G, Wedegaertner FR, Liersch J, et al. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol. 2005;10:283-288.
50. Koethe D, Juelicher A, Nolden BM, et al. OxcarbazepineVefficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res. 2007;31:1188-1194.
51. Hillbom M, Tokola R, Kuusela V, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6:223-226.
52. Myrick H, Brady KT, Malcolm R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse. 2000;26:155-160.
53. Lambie DG, Johnson RH, Vijayasenan ME, et al. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry. 1980;14:213-215.
54. Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582-1588.
55. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
56. Anton RF, Myrick H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009;29:334-342.
57. Bonnet U, Hamzavi-Abedi R, Specka M, et al. An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. Alcohol Alcohol. 2010;45:143-145.
58. Bonnet U, Specka M, Leweke FM, et al. Gabapentin's acute effect on mood profileVa controlled study on patients with alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31: 434-438.
59. Gold JA, Rimal B, Nolan A, et al. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med. 2007; 35:724-730.
60. Salloum IM, Cornelius JR, Daley DC, et al. The utility of diazepam loading in the treatment of alcohol withdrawal among psychiatric inpatients. Psychopharmacol Bull. 1995;31:305-310.
61. Manikant S, Tripathi BM, Chavan BS. Loading dose diazepam therapy for alcohol withdrawal state. Indian J Med Res. 1993;98:170-173.